Current management options for the treatment of refractory postoperative cystoid macular edema: A systematic review

IF 5.1 2区 医学 Q1 OPHTHALMOLOGY
Layla J. Bunjo , Stephen Bacchi , James Pietris , Weng Onn Chan
{"title":"Current management options for the treatment of refractory postoperative cystoid macular edema: A systematic review","authors":"Layla J. Bunjo ,&nbsp;Stephen Bacchi ,&nbsp;James Pietris ,&nbsp;Weng Onn Chan","doi":"10.1016/j.survophthal.2024.03.005","DOIUrl":null,"url":null,"abstract":"<div><p>Post-operative cystoid macular edema (PCME) is an important complication following intraocular surgery that often resolves spontaneously without treatment. In some cases, PCME may persist despite initial medical therapy, which can adversely impact visual outcomes. Various topical, intraocular and systemic treatments exist for the prevention and management of cystoid macular edema; however, there is no consensus on treatment of refractory cases in the postoperative setting. In accordance with the PRISMA guidelines, we systematically reviewed 68 articles describing management options and their outcomes for treatment-resistant cases of PCME. The most commonly reported treatments included steroid (39 studies) and biological-based (17 studies) therapies. We provide an overview of the treatment options for refractory PCME.</p></div>","PeriodicalId":22102,"journal":{"name":"Survey of ophthalmology","volume":"69 4","pages":"Pages 606-621"},"PeriodicalIF":5.1000,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Survey of ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0039625724000195","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Post-operative cystoid macular edema (PCME) is an important complication following intraocular surgery that often resolves spontaneously without treatment. In some cases, PCME may persist despite initial medical therapy, which can adversely impact visual outcomes. Various topical, intraocular and systemic treatments exist for the prevention and management of cystoid macular edema; however, there is no consensus on treatment of refractory cases in the postoperative setting. In accordance with the PRISMA guidelines, we systematically reviewed 68 articles describing management options and their outcomes for treatment-resistant cases of PCME. The most commonly reported treatments included steroid (39 studies) and biological-based (17 studies) therapies. We provide an overview of the treatment options for refractory PCME.

目前治疗难治性术后囊样黄斑水肿的方法:系统综述。
术后囊样黄斑水肿(PCME)是眼内手术后的一种重要并发症,通常无需治疗即可自行消退。在某些情况下,尽管最初接受了药物治疗,但 PCME 可能会持续存在,这可能会对视觉效果产生不利影响。目前有多种局部、眼内和全身治疗方法可用于预防和治疗囊样黄斑水肿,但对于术后难治性病例的治疗还没有达成共识。根据 PRISMA 指南,我们系统回顾了 68 篇描述 PCMO 耐药病例治疗方案及其结果的文章。最常报道的治疗方法包括类固醇疗法(39 项研究)和生物疗法(17 项研究)。我们对难治性 PCMO 的治疗方案进行了概述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Survey of ophthalmology
Survey of ophthalmology 医学-眼科学
CiteScore
10.30
自引率
2.00%
发文量
138
审稿时长
14.8 weeks
期刊介绍: Survey of Ophthalmology is a clinically oriented review journal designed to keep ophthalmologists up to date. Comprehensive major review articles, written by experts and stringently refereed, integrate the literature on subjects selected for their clinical importance. Survey also includes feature articles, section reviews, book reviews, and abstracts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信